Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Prospect Capital Corporation — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.74 (market cap $6.04B), while Prospect Capital Corporation trades at $1.78 (market cap $974.22M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 6.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Prospect Capital Corporation for 78 Days on average.
| IOVA | PSEC | |
|---|---|---|
Market Cap | $6.04B | $974.22M |
Volume | 14,805,993 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $14.82 | $3.05 |
52-Week Low | $1.81 | $1.82 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $5.97B | $2.73B |
Dividend Yield | — | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PSEC trades at $1.80, down 2.17% today, with a bearish technical outlook showing 18 sell signals versus 5 buy signals. The company shows mixed fundamentals with a low P/B ratio of 0.33 but concerning profitability metrics including 1.01% ROE and negative revenue of -$407M for 2025. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.15 beating the $0.11 estimate. The stock pays a regular $0.04 monthly dividend, providing income appeal despite operational challenges.
PSEC presents a high-risk opportunity with significant challenges. The 62% NAV discount and consistent dividend payments offer value for income-focused investors, but persistent revenue volatility, negative cash flow, and bearish analyst sentiment (55% hold rating) suggest caution. Key risks include ongoing portfolio contraction and declining investment income, requiring careful monitoring of quarterly results and NAV stability for any turnaround signs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
